EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer

Population-based differences in treatment outcome following anticancer drug therapies

(2010) Brigette BY Ma et al.   LANCET ONCOLOGY

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

(2009) D. M. Jackman et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non–Small-Cell Lung Cancer and Poor Performance Status

(2009) Glenwood Goss et al.   JOURNAL OF CLINICAL ONCOLOGY

Issues in Using Progression-Free Survival When Evaluating Oncology Products

(2009) Thomas R. Fleming et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges

(2009) Sumithra J. Mandrekar et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers

(2009) R. M. Simon et al.   JNCI-Journal of the National Cancer Institute

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC

(2009) Helena Linardou et al.   Nature Reviews Clinical Oncology

A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy

(2008) E. Felip et al.   CLINICAL CANCER RESEARCH

Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib

(2008) Vincent A. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer

(2008) Tomasz Burzykowski et al.   JOURNAL OF CLINICAL ONCOLOGY

Role ofKRASandEGFRAs Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

(2008) Chang-Qi Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study

(2008) Lucio Crinò et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer

(2008) Riichiroh Maruyama et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

(2008) Edward S Kim et al.   LANCET

Molecular genetics of lung cancer in people who have never smoked

(2008) Janakiraman Subramanian et al.   LANCET ONCOLOGY

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

(2008) Helena Linardou et al.   LANCET ONCOLOGY

Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: A chromogenic in situ hybridization study of 182 patients

(2008) John Wen-Cheng Chang et al.   LUNG CANCER

Gefitinib (ZD1839): Therapy in selected patients with non-small cell lung cancer (NSCLC)?

(2008) Diego Dongiovanni et al.   LUNG CANCER

EGFR FISH versus mutation: Different tests, different end-points

(2008) Federico Cappuzzo   LUNG CANCER

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE